RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
TFA Therapeutics, Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026
$9.18+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
TFA Therapeutics statistics
Financials through Dec 31, 2025, price as of Oct 16, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.02B | $164.85M |
| Enterprise Value | $1.02B | $87.06M |
| PS Ratio | 819.11 | 3.60 |
Enterprise value
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 819.11 | 2.43 |
Income (trailing twelve months)
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Revenue | $1.25M | $57.94M |
| Gross Profit | $760.74K | $90.47M |
| Operating Income | -$141.13K | -$21.44M |
| Pretax Income | -$154.82K | -$14.45M |
| Net Income | -$154.82K | -$22.46M |
| EBITDA | -$141.13K | -$16.91M |
| EPS (Diluted) | $0.00 | -$0.83 |
Margins
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 61.1% | 52.3% |
| Operating Margin | -11.3% | -44.5% |
| Pretax Margin | -12.4% | -13.0% |
| Profit Margin | -12.4% | -39.2% |
| EBITDA Margin | -11.3% | -31.3% |
Returns
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -3.34% | -41.0% |
Growth
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -0.65% | 6.01% |
| Revenue Growth (3Y CAGR) | 185.9% | 2.25% |
Balance sheet
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.20K | $62.42M |
| Net Cash (Debt) | $3.20K | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | -$534.55K | $48.79M |
| Book Value Per Share | -$0.00 | $1.36 |
| Tangible Book Value | -$534.55K | $23.06M |
| Working Capital | -$4.19M | $75.77M |
Financial position
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.19 | 3.30 |
| Quick Ratio | 0.00 | 2.39 |
Cash flow (trailing twelve months)
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$35.85K | -$12.35M |
Efficiency
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.27 | 0.38 |
| Inventory Turnover | 0.72 | 2.67 |
| Revenue Per Employee | $77.83K | $398.96K |
| Profits Per Employee | -$9.68K | -$703.34K |
| Employee Count | 16 | 74 |
Dividends and yields
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -0.02% | -22.7% |
Shares
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 111,120,000 | 58,179,650 |
| Shares Change (YoY) | 0.00% | 11.1% |
| Float | 111,120,000 | 49,173,100 |
| Shares Held by Insiders | 0.00% | 11.6% |
Scores
| Measure | TFA Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 116.71 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from TFA Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.